Minimize

Welcome!

A comprehensive update from Theralase

Cory
April 6, 2017
Comments (4)

After a couple news releases this week we have Roger White, CEO and President of Theralase to provide an update. The Company has treated one patient and has two more enrolled. We discuss the progress of the trails and what investors can expect for the rest of the year. We also touch on the brain cancer division and the financial condition of Theralase.

Click here to visit the Theralase website.

Click download link to listen on this device: Download Show

Theralase Technologies
Discussion
4 Comments
    CFS
    Apr 06, 2017 06:23 PM

    Theralase’s lead PDC, TLD-1433, is based on the metal Ruthenium and is currently under clinical investigation in a Phase Ib clinical study for Non-Muscle Invasive Bladder Cancer.

    Does it also intend to use Osmium-based PDCs in future, possibly for other cancers?

    CFS
    Apr 06, 2017 06:25 PM

    Reference Article:
    http://onlinelibrary.wiley.com/doi/10.1111/php.12767/epdf?r3_referer=wol&tracking_action=preview_click&show_checkout=1&purchase_referrer=onlinelibrary.wiley.com&purchase_site_license=LICENSE_DENIED_NO_CUSTOMER

    Ulf
    Apr 06, 2017 06:22 PM

    Thanks for the interview. Exciting times ahead.

    Jason
    Apr 07, 2017 07:55 AM

    I’ve got my 3.660 shares at 27.5 🙂